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Purpose: Age-related macular degeneration (AMD) is a common blinding disease in the elderly population. AMD is
frequently complicated by choroidal neovascularization, causing irreversible losses in visual acuity. Proteins that induce
pathologic angiogenesis in other systems include angiogenin, a small protein involved in angiogenesis in tumor metastases.
Our goal was to determine if angiogenin participates in angiogenesis during choroidal neovascular membrane formation
in AMD.
Methods: The expression of angiogenin in the human retina and retinal pigment epithelium (RPE)-choroid was determined
using reverse-transcription (RT)-PCR and immunoblotting. Localization of angiogenin in human control eyes and in eyes
with choroidal neovascularization was determined using immunohistochemistry. Potential angiogenin-mediated effects
on endothelial cell migration, as well as angiogenin internalization by Rf/6a cells, were determined.
Results: Angiogenin was synthesized by the human choroid and retina and localized to normal and pathologic vasculature.
Angiogenin did not change the migratory behavior of Rf/6a chorioretinal endothelial cells; however, these cells did
internalize exogenous angiogenin in culture.
Conclusions: Chorioretinal endothelial cells bind and internalize angiogenin, a protein localized to the choroid in normal
eyes, as well as in some drusen and in neovascular membranes in AMD eyes. Angiogenin has been shown to participate
in angiogenesis in other tissues. Although angiogenin does not increase the migratory behavior of these cells, it may play
a role in other aspects of endothelial cell activation in neovascular AMD.
Age-related macular degeneration (AMD) is currently
the leading cause of irreversible vision loss in the western
world  [1].  This  disease  is  characterized  by  commonly
described landmarks including drusen and retinal pigment
epithelial  atrophy  [2–5].  Whereas  many  patients  do  not
advance  beyond  early  atrophic  AMD,  AMD  can  be
complicated by end-stage, severe attenuation of the retinal
pigment epithelium (RPE), termed geographic atrophy, or by
abnormal blood vessel growth from the choroid into the RPE
and/or  the  subretinal  space  [5–11].  This  complication  of
AMD, referred to as choroidal neovascularization (CNV),
severely  decreases  visual  acuity,  and  is  characterized  by
abnormal angiogenesis.
Numerous molecular pathways affect different facets of
angiogenesis, and may therefore be involved in promoting
neovascularization  in  human  patients  with  AMD  [12].
Vascular endothelial growth factor (VEGF)-signaling is the
best-characterized of these, and the recent development of
anti-VEGF therapy to treat patients with advanced AMD has
been  remarkably  successful  [13–15].  Other  mitogenic
polypeptides potentially involved in neovascular AMD may
include fibroblast growth factor-1 (FGF1), FGF2, transformin
growth factor (TGF)-β, or angiopoietins 1 and 2 [16–19]. An
improved understanding of other molecules that may regulate
angiogenesis  in  the  human  choroid  is  important  for  the
development of additional therapies, especially if anti-VEGF
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therapies are found to have other, unappreciated, ocular, or
systemic effects in some patients [20,21]. One protein that
may  be  involved  in  this  process  is  angiogenin,  a  small
polypeptide that shares one third of its amino acid sequence
with  the  enzyme,  pancreatic  RNase  (RNase)  A  1  [22].
Although the enzymatic activity of angiogenin is limited, it
has been shown to promote angiogenesis in other systems
[23–25]. We sought in this study to determine the localization
and physiologic effects of angiogenin in the choroid, and to
relate  these  findings  to  the  development  of  neovascular
membranes in AMD.
METHODS
Angiogenin reverse-transcription PCR in human choroid and
retina: Human donor eyes (n=3) were obtained from the Iowa
Lions Eye Bank (Iowa City, IA) within 5 h of death (eye ages
were 80, 84, and 87 years). All donor families fully consented,
and all experiments were performed in accordance with the
Declaration  of  Helsinki.  The  tissues  used  for  reverse-
transcription (RT)-PCR did not exhibit any sign of AMD.
RNA from temporal, extramacular punches of RPE-choroid
and retina was isolated separately, using the RNeasy mini-kit
according to manufacturer’s instructions (Qiagen, Valencia,
CA). Reverse transcription was performed using the High-
Capacity  cDNA  Reverse  Transcription  kit  (Applied
Biosystems,  Foster  City,  CA).  For  RT–PCR,  cDNA  was
pooled from three RPE-choroid punches. PCR was performed
(Biolase DNA polymerase kit; Bioline, Taunton, MA) using
the following conditions for 35 cycles: denaturing at 94 °C for
45 s, annealing at 62 °C for 30 s, and elongation at 72 °C for
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5761 min. The angiogenin primers used were designed from the
Ensembl #ENSG00000214274 sequence as follows: forward
primer,  5′-CGT  CCG  TGT  ACA  CAC  ACT  CA-3′,  and
reverse primer, 5′-GCA CGA AGA CCA ACA ACA AA-3′
(Integrated  DNA  Technologies,  Coralville,  IA).  PCR
products were separated on a 2% agarose gel (FisherBiotech
horizontal  electrophoresis  system;  Fisher  Scientific,
Pittsburgh, PA) at 135 V for approximately 45 min. Gels were
stained using ethidium bromide.
Angiogenin detection with immunoblotting: Retinal and RPE/
choroid tissue from the extramacular, temporal region of 3
human donor eyes was snap frozen in liquid N2 within 5 h post
mortem. Tissue was homogenized in PBS with 1% Triton
X-100 and complete protease inhibitor (Roche, Indianapolis,
IN).  Recombinant  angiogenin  (5  ng;  R&D  Systems,
Minneapolis, MN) or 20 µg of choroid or retinal protein was
mixed with an equal volume of 2× Laemmli buffer (BioRad
Laboratories, Inc., Hercules, CA), boiled for 5 min, and then
separated electrophoretically on a 4%–20% Tris-HCl gradient
sodium  dodecyl  sulfate  (SDS)  polyacrylamide  gel  as
described previously [26]. Next, proteins were blotted onto a
polyvinylidene  difluoride  (PVDF)  membrane  (BioRad
Laboratories, Inc., Hercules, CA). Following blocking in BSA
(BSA),  an  antibody  directed  against  angiogenin  (R&D
Systems)  was  employed  at  a  concentration  of  0.4  µg/ml,
followed  by  washing  of  the  membrane,  incubation  with
0.4 µg/ml peroxidase-conjugated species-specific secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and
detection using the ECL Plus kit (Amersham Biosciences,
Buckinghamshire, UK). As a loading control, anti-beta-actin
antibody (Santa Cruz Biotechnology) was used on blots that
were stripped with 10% SDS, 0.7% beta mercaptoethanol,
60 mM Tris Cl (pH 6.8) at 55 °C for 30 min.
Angiogenin  localization  using  immunohistochemistry:
Sections of 22 human donor eyes ranging from 60 to 90 years
of  age,  spanning  from  the  macula  to  the  ora  serrata  and
containing both retina and RPE/choroid, were collected and
fixed in 4% paraformaldehyde for 2 h within 8.5 h, post
mortem. All eyes were obtained from the Iowa Lions Eye
Bank  with  consent,  as  stated  above.  Eyes  included  two
samples with CNV and three with early AMD. The tissues
were infiltrated in increasing concentrations of sucrose (up to
20%) and then embedded in two parts 20% sucrose to one part
optimal cutting temperature medium (Sakura, Torrance, CA)
[27]. Frozen sections at a thickness of 7 µm were collected
using a cryostat.
Sections were blocked in 1% horse serum for 15 min. The
primary antibody used, at a concentration of 4 µg/ml, was an
antibody to human angiogenin raised in rabbits (Santa Cruz
Biotechnology). Immunolabeling was performed as described
previously [28]. Briefly, sections were incubated with anti-
angiogenin antibody for 1 h, rinsed, probed with biotinylated
secondary  antibody  and  avidin-horseradish  peroxidase
complex, and visualized using the Vector VIP development
kit  according  to  manufacturer's  instructions  (Vector
Laboratories, Burlingame, CA)
Assessment  of  angiogenin-mediated  choroidal  endothelial
cell  migration:  To  determine  whether  angiogenin  induces
migration of endothelial cells from the posterior pole, Rf/6a
cells (a primate chorioretinal endothelial cell line, American
Type Culture Collection, Manassas, VA) were seeded into the
upper  chamber  of  8  μm  pore  culture  inserts  (Millipore,
Billerica, MA) within a 24-well plate. Recombinant human
Figure 1. Angiogenin is expressed in the
human  retina  and  retinal  pigment
epithelium (RPE)-choroid. A: Reverse-
transcription  (RT)-PCR  results.
Angiogenin cDNA was amplified from
both  human  retina  (Ret)  and  choroid
(Ch)  tissues.  Experiments  were
performed  with  (+)  and  without  (−)
reverse transcriptase enzyme, the latter
serving  as  controls.  B:  western  blot
results show that the angiogenin protein
is detectable only in the retinal pigment
epithelium-choroid samples (left panel).
Recombinant human angiogenin protein
(rAng)  was  detected  at  the  correct
molecular weight (14 kDa) with the anti-
angiogenin  antibody  as  a  positive
control. The stripped blot, probed with
anti-actin antibody (right panel) shows
even  loading  between  retinal  and
choroidal samples.
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577Figure 2. Angiogenin localization in human eyes. Labeling of angiogenin is shown in a normal macular choroid (A), in which angiogenin is
expressed on the endothelial cells of the choriocapillaris and large vessels, as well as localized to intercapillary pillars. Modest anti-angiogenin
labeling is detected in some extramacular drusen (C and D, asterisks). In some donors, approximately 50% of the hard drusen showed weak
immunoreactivity (C). Minor labeling of a hyaline druse (D, asterisk) was observed in an 83-year-old female with neovascular age related
macular degeneration (AMD), compared to an adjacent section in which the primary antibody was omitted (E). Endothelial cells in a
neovascular membrane (F) from the macula of human donor eye with advanced AMD were also reactive with anti-angiogenin antibody. The
presence of angiogenin in the neovascular membrane vessels indicates that it may play a role in the pathophysiology of these cells in AMD.
Controls in which primary antibodies are omitted are shown for normal tissue (B), drusen (E), and neovascular tissue (G). Scale bar represents
50 μm.
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578angiogenin protein was added to the lower chamber, diluted
in serum-free medium at a concentration of 0.5 μg/ml, which
is 2× the normal human serum concentration [29]. Elastin
derived peptides were used at a concentration of 1.0 μg/ml as
a positive control [30] and an equal volume of protein diluent
(Hank's Buffered Salt Solution-HBSS) was used as a negative
control. All experiments were performed in triplicate. Cells
were allowed to migrate for 8 h. Cells that migrated to the
lower  surface  of  the  insert were counted using scanning
electron  microscopy  (SEM)  as  described  previously [30].
Statistical analysis was performed using Student’s t-test.
Angiogenin uptake by chorioretinal endothelial cells: The
internalization of angiogenin by Rf/6a cells was determined.
Cells were cultured in F12 medium supplemented with 1%
fetal bovine serum (FBS), 20 ng/ml bFGF [31], and penicillin/
streptomycin on glass coverslips for 24 h. The cultures were
not  allowed  to  reach  confluency,  to  maximize  the
internalization of protein. Recombinant human angiogenin
protein (1 µg/ml) or 0.1% BSA control protein was added to
the medium of the cultures for 24 h. Cells were then fixed for
10  min  in  4%  paraformaldehyde  (pH  7.4),  and
immunocytochemistry  was  performed  using  an  antibody
directed against angiogenin (Santa Cruz Biotechnology) as
described above for tissue sections, except that Alexa-546
conjugated secondary antibodies (Invitrogen, Eugene, OR)
were  used  to  detect  angiogenin.  Phalloidin  (Invitrogen,
Eugene, OR) was added to the secondary antibody incubation
to visualize filamentous actin. Cells were imaged using an
Olympus  BX41  microscope  (Olympus,  Tokyo,  Japan)
equipped with fluorescent filter sets and a SPOT-RT camera
(Diagnostic  Instruments;  Burlingame,  CA).  Independent
images for angiogenin, actin, and diamidino-2-phenylindole
(DAPI) were collected separately and merged.
RESULTS
Expression of angiogenin in human retina and choroid using
PCR: To determine if the gene for angiogenin was expressed
in the human retina and choroid samples, non-quantitative
PCR was performed. Reverse-transcribed mRNA transcripts
for the angiogenin gene were amplified in both the retina and
choroid samples (Figure 1A).
Angiogenin protein expression in human retina and choroid
using immunoblotting: Western blots of human RPE-choroid
protein  probed  with  anti-angiogenin  antibody  showed  the
expression of a single immunoreactive band at the expected
molecular weight of 14 kDa (Figure 1B) and at the same
position on the blot as recombinant protein. In contrast to its
mRNA, angiogenin protein was not detected in the retina
samples using immunoblotting.
Localization of angiogenin in human retina and choroid: To
determine the cells responsible for endogenous expression of
angiogenin in the human choroid samples, anti-angiogenin
immunohistochemistry was performed. In labeled sections,
the choriocapillary pillars were positive, as well as capillary
endothelial  cells  and  endothelial  cells  in  larger  choroidal
vessels (Figure 2A). This pattern indicated that the angiogenin
peptide was present in the human choroid in vivo. Sections
that  were  not  exposed  to  primary  antibodies  showed  no
labeling (Figure 2B). There was variable labeling of drusen in
sections from patients with AMD. Many soft drusen (i.e., large
drusen with sloping borders that were >63 µm) had very
sparse, punctate labeling (not shown), while nodular drusen
either had moderate labeling or no labeling (Figure 2C,D,E).
Tissues  from  patients  with  neovascular  AMD  exhibited
angiogenin labeling on the endothelial cells in the choroid, as
well as on those within the neovascular membranes (Figure
2F,G).
Effects  of  angiogenin  on  chorioretinal  endothelial  cell
migration: A Boyden’s chamber migration assay was used to
measure the changes in migration of chorioretinal endothelial
cells in the presence of elevated levels of angiogenin protein.
The presence of angiogenin at the tested concentration did not
affect the migratory response of chorioretinal endothelial cells
in this assay (Figure 3). The t-test p value was 0.3. Exposure
Figure 3. Angiogenin does not promote
migration  of  chorioretinal  endothelial
cells. Angiogenin protein (ANG) did not
promote endothelial cell migration, and
migration  was  comparable  to  that
observed  with  Hank's  Buffered  Salt
Solution  (HBSS)  alone.  The  positive
control, elastin derived peptides (EDP),
resulted  in  a  marked  increase  in
migration  as  noted  previously  [30].
Asterisk (*) indicates a p value of <0.01.
NS means not significant.
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579of EC to the positive control, elastin fragments, resulted in a
significant increase in migration compared to the control, as
previously described [30] (p<0.01).
Nuclear  translocation  of  angiogenin  by  chorioretinal
endothelial cells: Chorioretinal cells that were incubated with
the  recombinant  human  angiogenin  protein  showed
significantly higher angiogenin labeling within the cytoplasm
and the nucleus than within the control cells that had been pre-
incubated with BSA only (Figure 4), indicating that these cells
were capable of angiogenin uptake. Cells in both experimental
groups demonstrated some labeling of angiogenin due to the
presence of endogenous protein.
DISCUSSION
The activation of endothelial cells and the development of
choroidal neovascular membranes in patients with AMD are
complex events that are not well defined. Although there are
very effective anti-VEGF treatments currently in use for the
treatment  of  existing  neovascular  membranes,  the
precipitating causes underlying the formation and growth of
choroidal neovascular membranes (CNVMs) is likely to be
complex.  Determining  these  other  events  will  further  our
knowledge of the causal mechanisms occurring in AMD and
will provide more complete therapeutic options.
We hypothesized that angiogenin may elicit neovascular
behaviors in ocular endothelial cells. Although the role of
angiogenin  in  neovascular  eye  diseases  has  not  been
established, its concentration in the vitreous of proliferative
diabetic retinopathy patients has been shown to be elevated
[32,33]. This finding indicates a possible role for angiogenin
in  the  retinal  neovascularization  that  occurs  in  diabetic
retinopathy.
In our studies, angiogenin does not appear to increase
migration—one  measure  of  angiogenic  behavior—in
chorioretinal  endothelial  cells.  The  positive  control  for
choroidal  EC  migration,  elastin  peptides,  did  promote
migration as described previously [30], demonstrating that the
EC were capable of responding to chemotactic stimuli. We
did not assess other potential roles of angiogenin in functions
associated  with  choroidal  neovascularization,  such  as
Figure 4. Endothelial cells internalize angiogenin in culture. Rf/6a chorioretinal endothelial cells incubated with recombinant human
angiogenin (A-C) and with the control protein, BSA (BSA; D-F). Cells exposed to angiogenin exhibit intense angiogenin labeling, indicating
that they actively import the protein. Cells that were not exposed to angiogenin demonstrated only faint labeling in the cytosol, attributed to
endogenous angiogenin. Filamentous actin is labeled with phalloidin (A, D) and nuclei are labeled with diamidino-2-phenylindole (DAPI;
blue).
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580extracellular matrix turnover, tubulogenesis, or proliferation.
It is possible that angiogenin participates in some, but not
other, aspects of angiogenesis in the aging eye.
Chorioretinal endothelial cells were found to internalize
angiogenin peptides from the microenvironment, suggesting
that these cells express angiogenin receptor(s), which are yet
to  be  conclusively  identified  [34,35].  In  other  systems,
angiogenin  exerts  complex  effects  on  cell  behavior  that
include direct interaction with filamentous actin [36], B/Akt
kinase activation, and rRNA synthesis [31]. Since Rf/6a cells
are  able  to  bind  angiogenin  and  import  it  from  their
microenvironment, it is possible that this protein participates
in  the  regulation  of  some  aspects  of  inflammation  and/or
angiogenesis  in  the  human  choroid,  central  features  of
neovascular AMD.
Finally, we found that angiogenin is present within some
drusen, which is intriguing since these deposits occasionally
appear to be a substrate for angiogenesis (R.F.M., unpublished
observations). Moreover, angiogenin was localized to both the
normal vasculature and the pathologic endothelium in eyes
with neovascular membranes, suggesting that angiogenin may
be  necessary  in  maintaining  the  vasculature  and  that
angiogenin polypeptides are present during the pathologic
development of AMD. A comprehensive understanding of
angiogenin  and  its  potential  receptor(s)  in  normal  and
diseased  human  eyes,  and  its  effects  on  endothelial  cell
physiology and biochemistry, may provide further insights
into AMD disease progression.
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